SMAD3-driven cell state transitions underpin immunoresistance in bladder cancer
- 1University College Dublin
Abstract
Despite the clinical success of anti-PD-1/PD-L1 immunotherapy in a subset of patients with high-risk bladder cancer (BLCA), most tumors remain refractory to treatment. We hypothesized that immunotherapy resistance is encoded within the intrinsic signaling state of BLCA cells and arises through specific cell-state transitions that precede therapeutic exposure. To test this hypothesis, we applied a cell State Transition Assessment and Regulation (cSTAR) framework to identify key signaling modules and aberrant causal network connections that (i) drive oncogenic progression and acquisition of aggressive phenotypes and (ii) govern BLCA cell susceptibility to T cell-mediated cytotoxicity. cSTAR analysis identified TGF{beta}/SMAD3 signaling as the principal driver of both oncogenic transformation and immunoresistance in BLCA cells. Inhibiting SMAD3 sensitized BLCA cells to PD-1-expressing Jurkat cells and primary human CD4+ T cell-mediated cytotoxicity through suppression of autophagy and activation of multiple cell death pathways. By integrating cell state transition analysis with functional immune co-culture assays, our work demonstrates that tumor cell state transitions control sensitivity to T cell killing, complementing established immune-intrinsic mechanisms of immunotherapy response.
Related
- Speed-driven transitions between discrete and rhythmic dynamics in walking revealed by kinematic smoothness and muscle synergies
- Egyptian Bladder Cancer: Interrupted Time Series Analysis of Schistosoma haematobium Control and Cancer Incidence, 1960-2020
- Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures
- 345 Neoantigen-targeted adoptive cell therapy in bladder cancer: feasibility of isolating and enriching tumor-reactive infiltrating lymphocytes
- Reprogramming innate immune memory in bladder cancer: the proposed bone marrow–bladder axis and next-generation BCG-based immunotherapies
BibTeX
@misc{robertson2026smad3driven,
title = {{SMAD3-driven cell state transitions underpin immunoresistance in bladder cancer}},
author = {S. Y. T. Robertson and J. Yang and N. O. Carragher and A. Munro and N. Rauch and T. Sevrin and K. Wynne and W. kolch and O. S. Rukhlenko and B. N. Kholodenko},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.21.760742},
url = {https://www.biorxiv.org/content/10.64898/2026.10.21.760742v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - SMAD3-driven cell state transitions underpin immunoresistance in bladder cancer
AU - S. Y. T. Robertson
AU - J. Yang
AU - N. O. Carragher
AU - A. Munro
AU - N. Rauch
AU - T. Sevrin
AU - K. Wynne
AU - W. kolch
AU - O. S. Rukhlenko
AU - B. N. Kholodenko
PY - 2026
DA - 2026/10/21
PB - bioRxiv
DO - 10.64898/2026.10.21.760742
UR - https://www.biorxiv.org/content/10.64898/2026.10.21.760742v1
AB - Despite the clinical success of anti-PD-1/PD-L1 immunotherapy in a subset of patients with high-risk bladder cancer (BLCA), most tumors remain refractory to treatment. We hypothesized that immunotherapy resistance is encoded within the intrinsic signaling state of BLCA cells and arises through specific cell-state transitions that precede therapeutic exposure. To test this hypothesis, we applied a cell State Transition Assessment and Regulation (cSTAR) framework to identify key signaling modules and aberrant causal network connections that (i) drive oncogenic progression and acquisition of aggressive phenotypes and (ii) govern BLCA cell susceptibility to T cell-mediated cytotoxicity. cSTAR analysis identified TGF{beta}/SMAD3 signaling as the principal driver of both oncogenic transformation and immunoresistance in BLCA cells. Inhibiting SMAD3 sensitized BLCA cells to PD-1-expressing Jurkat cells and primary human CD4+ T cell-mediated cytotoxicity through suppression of autophagy and activation of multiple cell death pathways. By integrating cell state transition analysis with functional immune co-culture assays, our work demonstrates that tumor cell state transitions control sensitivity to T cell killing, complementing established immune-intrinsic mechanisms of immunotherapy response.
ER -